Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J. & Hsueh, P.-R. Extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Brokers 55, 105924 (2020).
Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Traits of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141â154 (2021).
Pfortmueller, C. A., Spinetti, T., Urman, R. D., Luedi, M. M. & Schefold, J. C. COVID-19-associated acute respiratory misery syndrome (CARDS): Present information on pathophysiology and ICU treatmentâA story overview. Greatest Pract. Res. Clin. Anaesthesiol. 35, 351â368 (2021).
Lin, L., Lu, L., Cao, W. & Li, T. Speculation for potential pathogenesis of SARS-CoV-2 infectionâa overview of immune modifications in sufferers with viral pneumonia. Emerg. Microbes Infect. 9, 727â732 (2020).
Edalat, F. et al. Delving into revolutionary SARS-CoV-2 vaccine approaches: Molecular and virological examinations; rules of SARS-CoV-2 vaccine platform. Vacunas https://doi.org/10.1016/j.vacun.2023.08.002 (2023).
Baruah, C., Devi, P. & Sharma, D. Ok. Sequence evaluation and construction prediction of SARS-CoV-2 accent proteins 9b and ORF14: Evolutionary evaluation signifies shut relatedness to bat coronavirus. Biomed. Res. Int. 2020, 7234961 (2020).
Kakavandi, S. et al. Structural and non-structural proteins in SARS-CoV-2: Potential elements to COVID-19 therapy or prevention of development of associated illnesses. Cell Commun. Sign. 21, 110 (2023).
Jawad, B., Adhikari, P., Podgornik, R. & Ching, W.-Y. Key interacting residues between RBD of SARS-CoV-2 and ACE2 receptor: Mixture of molecular dynamics simulation and density practical calculation. J. Chem. Inf. Mannequin. 61, 4425â4441 (2021).
Bai, Z., Cao, Y., Liu, W. & Li, J. The SARS-CoV-2 nucleocapsid protein and its position in viral construction, organic capabilities, and a possible goal for drug or vaccine mitigation. Viruses 13, 1115 (2021).
Pan, P. et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat. Commun. 12, 4664 (2021).
Chen, Ok. et al. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-β manufacturing. Viruses 13, 47 (2020).
Luo, L. et al. SARS-CoV-2 nucleocapsid protein part separates with G3BPs to disassemble stress granules and facilitate viral manufacturing. Sci. Bull. 66, 1194â1204 (2021).
Wang, S. et al. Focusing on liquidâliquid part separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS exercise. Nat. Cell Biol. 23, 718â732 (2021).
Li, C., He, Q., Qian, H. & Liu, J. Overview of the pathogenesis of COVID-19. Exp. Ther. Med. 22, 1â10 (2021).
Singh, R., Letai, A. & Sarosiek, Ok. Regulation of apoptosis in well being and illness: the balancing act of BCL-2 household proteins. Nat. Rev. Mol. Cell Biol. 20, 175â193 (2019).
Thompson, M. R., Kaminski, J. J., Kurt-Jones, E. A. & Fitzgerald, Ok. A. Sample recognition receptors and the innate immune response to viral an infection. Viruses 3, 920â940 (2011).
Lavatory, Y.-M. & Gale, M. Immune signaling by RIG-I-like receptors. Immunity 34, 680â692 (2011).
Znaidia, M., Demeret, C., van der Werf, S. & Komarova, A. V. Characterization of SARS-CoV-2 evasion: Interferon pathway and therapeutic choices. Viruses 14, 1247 (2022).
Kim, Y.-M. & Shin, E.-C. Kind I and III interferon responses in SARS-CoV-2 an infection. Exp. Mol. Med. 53, 750â760 (2021).
Wang, Y. C. et al. SARS-CoV-2 nucleocapsid protein, fairly than spike protein, triggers a cytokine storm originating from lung epithelial cells in sufferers with COVID-19. An infection https://doi.org/10.1007/s15010-023-02142-4 (2023).
Shuaib, M. et al. Impression of the SARS-CoV-2 nucleocapsid 203K/204R mutations on the inflammatory immune response in COVID-19 severity. Genome Med. 15, 54 (2023).
Apte, A. & Singh, S. AlleleID: A pathogen detection and identification system. Strategies Mol. Biol. 402, 329â346 (2007).
Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, Ok. MEGA X: Molecular evolutionary genetics evaluation throughout computing platforms. Mol. Biol. Evol. 35, 1547 (2018).
Ivanisenko, N. V., Seyrek, Ok., Kolchanov, N. A., Ivanisenko, V. A. & Lavrik, I. N. The position of demise area proteins in host response upon SARS-CoV-2 an infection: Modulation of programmed cell demise and translational purposes. Cell Demise Discov. 6, 101 (2020).
Wang, W., Chen, J., Yu, X. & Lan, H.-Y. Signaling mechanisms of SARS-CoV-2 Nucleocapsid protein in viral an infection, cell demise and irritation. Int. J. Biol. Sci. 18, 4704 (2022).
Mu, J. et al. SARS-CoV-2 N protein antagonizes sort I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 6, 65 (2020).
Mogensen, T. H. & Paludan, S. R. Molecular pathways in virus-induced cytokine manufacturing. Microbiol. Mol. Biol. Rev. 65, 131â150 (2001).
Pan, P. et al. SARS-CoV-2 N protein enhances the anti-apoptotic exercise of MCL-1 to advertise viral replication. Sign Transduct. Goal. Ther. 8, 1â15 (2023).
Liang, C., Oh, B.-H. & Jung, J. U. Novel capabilities of viral anti-apoptotic elements. Nat. Rev. Microbiol. 13, 7â12 (2015).
Park, M. H. & Hong, J. T. Roles of NF-κB in most cancers and inflammatory illnesses and their therapeutic approaches. Cells 5, 15 (2016).
Ren, Y. et al. SARS-CoV-2 membrane glycoprotein M triggers apoptosis with the help of nucleocapsid protein N in cells. Entrance. Cell. Infect. Microbiol. 11, 706252 (2021).
Wang, W. et al. SARS-CoV-2 N protein induces acute kidney damage by way of Smad3-dependent G1 cell cycle arrest mechanism. Adv. Sci. 9, 2103248 (2022).
Yuen, C.-Ok. et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 perform as potent interferon antagonists. Emerg. Microbes Infect. 9, 1418â1428 (2020).
Neufeldt, C. J. et al. SARS-CoV-2 an infection induces a pro-inflammatory cytokine response via cGAS-STING and NF-κB. Commun. Biol. 5, 45 (2022).
Freitas, R. S., Crum, T. F. & Parvatiyar, Ok. SARS-CoV-2 spike antagonizes innate antiviral immunity by focusing on interferon regulatory issue 3. Entrance. Cell. Infect. Microbiol. 11, 1350 (2022).
Banerjee, A. et al. Experimental and pure proof of SARS-CoV-2-infection-induced activation of sort I interferon responses. IScience 24, 102477 (2021).
Shemesh, M. et al. SARS-CoV-2 suppresses IFNβ manufacturing mediated by NSP1, 5, 6, 15, ORF6 and ORF7b however doesn’t suppress the consequences of added interferon. PLoS Pathog. 17, e1009800 (2021).
Kasuga, Y., Zhu, B., Jang, Ok.-J. & Yoo, J.-S. Innate immune sensing of coronavirus and viral evasion methods. Exp. Mol. Med. 53, 723â736 (2021).
Oh, S. J. & Shin, O. S. SARS-CoV-2 nucleocapsid protein targets RIG-I-like receptor pathways to inhibit the induction of interferon response. Cells 10, 530 (2021).
Gori Savellini, G., Anichini, G., Gandolfo, C. & Cusi, M. G. SARS-CoV-2 N protein targets TRIM25-mediated RIG-I activation to suppress innate immunity. Viruses 13, 1439 (2021).
Feng, Ok. et al. SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses. J. Med. Virol. 95, e28881 (2023).
Yoo, J.-S. et al. SARS-CoV-2 inhibits induction of the MHC class I pathway by focusing on the STAT1-IRF1-NLRC5 axis. Nat. Commun. 12, 6602 (2021).
Liu, Y., Olagnier, D. & Lin, R. Host and viral modulation of RIG-I-mediated antiviral immunity. Entrance. Immunol. 7, 662 (2017).
Hasan, A. et al. Enhancement of IL-6 manufacturing induced by SARS-CoV-2 Nucleocapsid protein and Bangladeshi COVID-19 patientsâ sera. Viruses 15, 2018 (2023).
Stepanenko, A. A. & Heng, H. H. Transient and secure vector transfection: Pitfalls, off-target results, artifacts. Mutat. Res. Rev. Mutat. Res. 773, 91â103 (2017).
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.